Transgene: new data to come on TG4050 vaccine

(CercleFinance.com) - Transgene will present a poster on the 24-month median follow-up data from the randomized Phase I trial of its TG4050 individualized therapeutic vaccine at the 39th annual conference of the Society for Immunotherapy of Cancer (SITC).


The poster will highlight efficacy and recurrence-free survival results in patients with head and neck cancer.

The SITC will be held in Houston (Texas, USA) from November 6 to 10, 2024.
The abstract will be available on the SITC website from November 5, 2024 (3pm in Paris).

As a reminder, Transgene had presented data in April 2024 showing that all patients treated with TG4050 were still in disease-free clinical remission after a median follow-up of 18.6 months, while
3 out of 16 patients had relapsed in the observational arm during the same period.

Copyright (c) 2024 CercleFinance.com. All rights reserved.